source
- CVS split into two entities fails to address core issues in pharmacy benefit managementCVS Health is one of the largest U.S. companies, serving hundreds of millions of Americans and generating about $400 billion in annual revenue. It touches nearly every step of the drug supply chain…
- Zura Bio halts hidradenitis suppurativa program after tibulizumab fails phase 2 trialZura Bio announced it is ending development of tibulizumab for hidradenitis suppurativa after the drug did not meet the primary endpoint in a phase 2 study. The trial, called Tibushield, compared t…